Mulhearn, B.; Barton, A.; Viatte, S. Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis. J. Pers. Med.2019, 9, 46.
Mulhearn, B.; Barton, A.; Viatte, S. Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis. J. Pers. Med. 2019, 9, 46.
Mulhearn, B.; Barton, A.; Viatte, S. Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis. J. Pers. Med.2019, 9, 46.
Mulhearn, B.; Barton, A.; Viatte, S. Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis. J. Pers. Med. 2019, 9, 46.
Abstract
Tumour necrosis factor-α is a key mediator of inflammation in rheumatoid arthritis its discovery led to the development of highly successful anti-TNF therapy. Subsequently, other biologic drugs targeting immune pathways, namely interleukin-6 blockade, B cell depletion, and T cell co-stimulation blockade, have been developed. Not all patients respond to a biologic drug leading to a knowledge gap between biologic therapies available and the confident prediction of response. So far, genetic studies have failed to uncover clinically informative biomarkers to predict response. Given that the targets of biologics are immune pathways, immunological study has become all the more pertinent. Furthermore, advances in single cell technology have enabled the characterisation of many leucocyte subsets. Studying the blood immunophenotype may therefore define biomarker profiles relevant to each individual patient’s disease and treatment outcome. This review summarises our current understanding of how immune biomarkers might be able to predict treatment response to biologic drugs.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
